Latest news

Arthritis Australia launches ground-breaking Rheumatoid Arthritis patient-support website

Arthritis Australia, in partnership with the Australian Rheumatology Association, has launched a new online rheumatoid arthritis patient-support website. The free MyRA website provides individually tailored information designed to help people seize control and become active participants in their journey with the disease.

PIDA Accessible Packaging Design Special Award 2019

Ecolean received the GOLD award for the Accessible Packaging Design Special Award 2020. Congratulations to Ecolean for their innovative flexible pouch, and to Bannister Downs Dairy for being industry leaders in utilising this type of packaging for their products. The pouch design is lightweight, easy to grip and stable to pour. It features also features…

support-patients

UPDATED: Advice regarding Coronavirus (Covid-19) from the Australian Rheumatology Association

Due to the increasing number of infections in Australia from Coronavirus (Covid-19), we are aware of growing concerns raised by patients with chronic illnesses and medications that affect their immune system. Currently, there is no specific advice for immune- compromised patients.

Australian Rheumatology Association and Arthritis Australia Statement regarding the use of glucosamine for the treatment of Osteoarthritis

Recent media reports have raised concern over the use of glucosamine in the treatment of osteoarthritis.  These reports appear to be based on two unrelated recent events:   A change in recommendation by the American College of Rheumatology (ACR) [1] In October 2019 the ACR updated their guidelines for the management of osteoarthritis from a…

New campaign reveals blind spot for older Australians

Arthritis Australia is urging older Australians to look out for symptoms of silent inflammation that could put their eyesight at risk, and to speak to their doctor without delay. More than a thousand Australians over 50 years old are affected each year by Giant Cell Arteritis, an autoimmune disease where the body mistakenly attacks its…

support-patients

Arthritis Australia launches new Multicultural Resources

Non-English-speaking communities will have improved access to information about arthritis and its management with the launch today of a new series of arthritis information sheets in fourteen different languages.

A new approach to support specialist prescribing of bDMARDs

Arthritis Australia is part of an eight-member Consortium led by NPS MedicineWise, which is the  successful recipient of the ‘Value in Prescribing biological disease-modifying anti-rheumatic drugs (bDMARDs)’ government grant. The grant will fund a project to improve the use of bDMARDs to ensure the best health and economic outcomes from investment in these therapies. NPS…

support-patients

Online resource to help sufferers ease back pain

A comprehensive tool to help people manage back pain has been developed by a team of international health experts led by University of Queensland researchers.   Following extensive consultation with people living with lower back pain (LBP), MyBackPain.org.au was launched today to provide tailored, trustworthy information not readily found elsewhere. UQ School of Health and…

support-patients

Musculoskeletal conditions, including arthritis, now the most costly disease group in Australia

The health system cost of musculoskeletal conditions, including arthritis, was $12.5 billion in 2015-16, up from $5.7 billion in 2008-09. The cost of these conditions has more than doubled in less than a decade and has well and truly eclipsed the cost of cancer, cardiovascular disease and mental health conditions. ‘We simply cannot continue to ignore…

support-patients

$120,000 scholarship to combat ‘serious shortage’ of paediatric rheumatologists in Australia so kids with arthritis get the care they need

On offer is a two-year scholarship to support paediatricians and paediatric trainees interested in training in paediatric rheumatology.  The scholarship will be equivalent to the salary and on-costs of the position to which they are appointed, to a maximum of A$120,000 per year up to two years.